Tarek Bandali

All Publications

• 5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response. Journal of the American Academy of Dermatology Lin, C. P., Kibbi, N., Bandali, T., Hirotsu, K., Aasi, S. Z. 2024

  Abstract

  BACKGROUND: Complete clinical response (CCR) rates for squamous cell carcinoma in situ (SCCis) treated with 5-fluorouracil (5-FU) 5% cream range from 27-85%. Factors associated with CCR are not well-established.METHODS: Retrospective review of biopsy-proven primary SCCis diagnosed between 5/1/2019-4/30/2020 and treated with 5-FU 5% cream. Disease status at follow-up was recorded, with treatment failure defined as persistent or recurrent disease.RESULTS: The study included 149 SCCis cases, including 33.6% (50/149) arising in the context of immunosuppression. Eighteen cases failed treatment (10 persistent disease, 8 recurrent disease). By tumor size, CCR was noted in 128/144 (88.9%) tumors measuring <2 centimeters in diameter and 3/5 tumors ≥2 centimeters (60.0%, p=0.051). By treatment duration, CCR was observed in 4/7 (57.1%) tumors treated for <2 weeks, 72/83 (86.7%), tumors treated for 2 to <4 weeks, and 55/59 (93.2%) tumors treated for ≥4 weeks (p=0.019). On multivariate analysis, treatment failure was significantly associated with shorter treatment durations (OR 0.26; p=0.007) and increasing tumor size (OR 2.40; p=0.037).CONCLUSIONS: Shorter treatment duration and larger lesion size were significantly associated with failure of 5-FU in SCCis. Immunosuppression and anatomic location were not significant factors, supporting 5-FU use for SCCis in the immunosuppressed population and highlighting its versatility irrespective of anatomic location.

  View details for DOI 10.1016/j.jaad.2024.10.066

  View details for PubMedID 39521136

• Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma Bojanini, L., Herrera, M., Li, S., Bandali, T., Xu, N. Y., Ahmed, A. A., Khodadoust, M. S., Kim, Y. H. ELSEVIER. 2024: 1677-1678

  View details for DOI 10.1182/blood-2024-198783

  View details for Web of Science ID 001412765900033

• Koebnerized vitiligo vulgaris following laser treatment of lichen planus pigmentosus successfully treated with topical ruxolitinib. JAAD case reports Bandali, T., Voller, L., Ko, J., Kibbi, N. 2024; 53: 136-138

  View details for DOI 10.1016/j.jdcr.2024.07.033

  View details for PubMedID 39507484

• Genetic alteration of class I HLA in cutaneous T-cell lymphoma. Blood Kwang, A. C., Duran, G. E., Fernandez-Pol, S., Najidh, S., Li, S., Bastidas Torres, A. N., Wang, E. B., Herrera, M., Bandali, T. I., Kurtz, D. M., Kim, Y. H., Khodadoust, M. S. 2024

  Abstract

  Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCL). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides (MF) or Sézary syndrome (SS). Targeted DNA sequencing including coverage of HLA loci revealed at least one HLA abnormality in 26/65 patients (40%). Twelve unique somatic HLA mutations were identified across nine patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with decreased total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presentation of greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient receiving pembrolizumab, where resistance to pembrolizumab was associated with elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL.

  View details for DOI 10.1182/blood.2024024817

  View details for PubMedID 39388712